Acute intravascular hemolysis is rarely associated with platelet transfusion. Out-of-group single-donor platelets may cause hemolysis if the donor has high-titer ABO hemagglutinins. A 44-year-old woman, blood group A, was recently diagnosed with acute myeloid leukemia and was receiving chemotherapy. After the transfusion of apheresis platelets from a group O donor, back pain, hemoglobinuria, and hemoglobinemia developed, and her Hb dropped by 2.3 g per dL, despite the transfusion of 2 units of RBCs. Investigation revealed acute intravascular hemolysis with a positive DAT due to anti-A(1) on her RBCs. The donor's titer of anti-A(1) was greater than 16,000. Review of published cases raises the possibility that hemolytic reactions to out-of-group platelets may be more frequent since the use of apheresis platelets has increased.
Acute hemolytic transfusion reaction due to ABO incompatible plasma in a plateletapheresis concentrate
Evaluation of changes in hemoglobin levels associated with ABO-incompatible plasma in apheresis platelets
Intravascular hemolysis secondary to ABO incompatible platelet products. An underrecognized transfusion reaction
Hemolytic transfusion reaction in group-A patient receiving group-O blood containing immune anti-A antibodies in high titer
A CLINICAL STUDY OF TRANSFUSION REACTIONS: THE HEMOLYTIC EFFECT OF GROUP-O BLOOD AND POOLED PLASMA CONTAINING INCOMPATIBLE ISOAGGLUTININS
The effects of the transfusion of group O blood of high iso-agglùtinin titer into recipients of other blood groups
Platelet transfusion in the management of severe thrombocytopenia in neonatal intensive care unit patients
Transfusion of ABO-nonidentical platelets is not associated with adverse clinical outcomes in cardiovascular surgery patients
Platelet transfusions in infants with necrotizing enterocolitis do not lower mortality but may increase morbidity
ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies
Quality systems in automated plateletpheresis in hospital-based blood transfusion service in north India
A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10(9) per L versus 30 x 10(9) per L in allogeneic hematopoietic progenitor cell transplant recipients
Significant numbers of apheresis-derived group O platelet units have "high-titer" anti-A/A,B: implications for transfusion policy
Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions
Transfusion efficacy of ABO major-mismatched platelets (PLTs) in children is inferior to that of ABO-identical PLTs
Acute hemolytic transfusion reaction in a pediatric patient following transfusion of apheresis platelets
Factors affecting platelet yield and their impact on the platelet increment of patients receiving single donor PLT transfusion
A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies
ABO antibody titers are not predictive of hemolytic reactions due to plasma-incompatible platelet transfusions
Risks of hemolysis due to anti-A and anti-B caused by the transfusion of blood or blood components containing ABO-incompatible plasma
Humoral immunomodulatory effect of influenza vaccine in potential blood donors: implications for transfusion safety
Posttransfusion platelet count increments after ABO-compatible versus ABO-incompatible platelet transfusions in noncancer patients: an observational study
The impact of platelet additive solution apheresis platelets on allergic transfusion reactions and corrected count increment (CME)
Fetal anemia as a response to prophylactic platelet transfusion in the management of alloimmune thrombocytopenia
An evaluation of methods for producing low-titer group O whole blood to support military trauma resuscitation
Immunologic risks of whole blood: ABO compatibility, D alloimmunization, and transfusion-related acute lung injury
Potential impact of complement regulator deficiencies on hemolytic reactions due to minor ABO-mismatched transfusions
Comparison of ABO antibody titration, IgG subclasses and qualitative haemolysin test to reduce the risk of passive haemolysis associated with platelet transfusion
Hemolysis following an out-of-group platelet transfusion in an 8-month-old with Langerhans cell histiocytosis
Balancing risk and benefit: maintenance of a thawed Group A plasma inventory for trauma patients requiring massive transfusion
Safety profile of uncrossmatched, cold-stored, low-titer, group O+ whole blood in civilian trauma patients
Transfusion of platelets containing ABO-incompatible plasma: a survey of 3156 North American laboratories.
Antibody-mediated agglutination is the clumping of cells in the presence of antibody, which binds multiple cells together. This enhances the clearance of pathogens. Find the latest research on antibody-mediated agglutination here.
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.
AML: Role of LSD1 by CRISPR (Keystone)
Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.